153 related articles for article (PubMed ID: 7609083)
21. Deletion of the myristylation signal allows high-level production of the hepatitis B virus large surface glycoprotein preS1 with vaccinia virus recombinants.
Pfleiderer M; Falkner FG; Dorner F
Gene; 1996 Oct; 176(1-2):131-7. PubMed ID: 8918244
[TBL] [Abstract][Full Text] [Related]
22. The amino-terminal nine amino acid sequence of poliovirus capsid VP4 protein is sufficient to confer N-myristoylation and targeting to detergent-insoluble membranes.
Martín-Belmonte F; López-Guerrero JA; Carrasco L; Alonso MA
Biochemistry; 2000 Feb; 39(5):1083-90. PubMed ID: 10653654
[TBL] [Abstract][Full Text] [Related]
23. Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans.
Ansardi DC; Porter DC; Morrow CD
J Virol; 1993 Jun; 67(6):3684-90. PubMed ID: 8388519
[TBL] [Abstract][Full Text] [Related]
24. Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures.
Ansardi DC; Porter DC; Morrow CD
J Virol; 1991 Apr; 65(4):2088-92. PubMed ID: 1848318
[TBL] [Abstract][Full Text] [Related]
25. Expression of large hepatitis B envelope protein mutants using a new expression vector.
Korec E; Gerlich WH
Arch Virol; 1992; 122(3-4):367-71. PubMed ID: 1731699
[TBL] [Abstract][Full Text] [Related]
26. Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames.
Mueller S; Wimmer E
J Virol; 1998 Jan; 72(1):20-31. PubMed ID: 9420196
[TBL] [Abstract][Full Text] [Related]
27. Poliovirus mutants at histidine 195 of VP2 do not cleave VP0 into VP2 and VP4.
Hindiyeh M; Li QH; Basavappa R; Hogle JM; Chow M
J Virol; 1999 Nov; 73(11):9072-9. PubMed ID: 10516013
[TBL] [Abstract][Full Text] [Related]
28. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.
Kohara M; Abe S; Komatsu T; Tago K; Arita M; Nomoto A
J Virol; 1988 Aug; 62(8):2828-35. PubMed ID: 2839704
[TBL] [Abstract][Full Text] [Related]
29. Poliovirus capsid proteins derived from P1 precursors with glutamine-valine cleavage sites have defects in assembly and RNA encapsidation.
Ansardi DC; Morrow CD
J Virol; 1993 Dec; 67(12):7284-97. PubMed ID: 8230452
[TBL] [Abstract][Full Text] [Related]
30. A Gly1 to Ala substitution in poliovirus capsid protein VP0 blocks its myristoylation and prevents viral assembly.
Marc D; Girard M; van der Werf S
J Gen Virol; 1991 May; 72 ( Pt 5)():1151-7. PubMed ID: 1851815
[TBL] [Abstract][Full Text] [Related]
31. Engineering poliovirus as a vaccine vector for the expression of diverse antigens.
Andino R; Silvera D; Suggett SD; Achacoso PL; Miller CJ; Baltimore D; Feinberg MB
Science; 1994 Sep; 265(5177):1448-51. PubMed ID: 8073288
[TBL] [Abstract][Full Text] [Related]
32. Studies towards the potential of poliovirus as a vector for the expression of HPV 16 virus-like-particles.
van Kuppeveld FJ; de Jong A; Dijkman HB; Andino R; Melchers WJ
FEMS Immunol Med Microbiol; 2002 Nov; 34(3):201-8. PubMed ID: 12423772
[TBL] [Abstract][Full Text] [Related]
33. Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system.
Lee SG; Kim DY; Hyun BH; Bae YS
J Virol; 2002 Feb; 76(4):1649-62. PubMed ID: 11799160
[TBL] [Abstract][Full Text] [Related]
34. Dicistronic polioviruses as expression vectors for foreign genes.
Alexander L; Lu HH; Gromeier M; Wimmer E
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S57-60. PubMed ID: 7865334
[TBL] [Abstract][Full Text] [Related]
35. Isolation of a recombinant type 3/type 2 poliovirus with a chimeric capsid VP1 from sewage in Shandong, China.
Tao Z; Wang H; Xu A; Zhang Y; Song L; Zhu S; Li Y; Yan D; Liu G; Yoshida H; Liu Y; Feng L; Chosa T; Xu W
Virus Res; 2010 Jun; 150(1-2):56-60. PubMed ID: 20206214
[TBL] [Abstract][Full Text] [Related]
36. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
37. Allele-specific adaptation of poliovirus VP1 B-C loop variants to mutant cell receptors.
Liao S; Racaniello V
J Virol; 1997 Dec; 71(12):9770-7. PubMed ID: 9371643
[TBL] [Abstract][Full Text] [Related]
38. Temperature-sensitive poliovirus mutant fails to cleave VP0 and accumulates provirions.
Compton SR; Nelsen B; Kirkegaard K
J Virol; 1990 Sep; 64(9):4067-75. PubMed ID: 2166805
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell.
Couderc T; Hogle J; Le Blay H; Horaud F; Blondel B
J Virol; 1993 Jul; 67(7):3808-17. PubMed ID: 8389907
[TBL] [Abstract][Full Text] [Related]
40. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.
Bouchard MJ; Lam DH; Racaniello VR
J Virol; 1995 Aug; 69(8):4972-8. PubMed ID: 7609067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
